The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BOPA 2017 | New additions: novel agents to boost treatment of multiple myeloma
Alberto Rocci, MD from the Central Manchester University Hospital, Manchester, UK discusses the encouraging data from recent clinical trials, looking to add novel agents to existing drug combinations for the treatment of multiple myeloma. Dr Rocci explains that by adding on novel agents, it may be possible to improve depth of response, progression-free survival and even overall survival. This interview was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK. This content has been supported by Napp Pharmaceuticals through an unrestricted educational grant to Magdalen Medical Publishing.The company has had no influence on the production of the content.
